CURRICULUM VITAE AJAY VERMA, M.D., Ph.D. WORK ADDRESS: Biogen, 14, Cambridge Center, Bio 6 Cambridge, MA 02142 Telephone: +1-617-679-4311 Mobile: +1-857-334-0648 Fax: +1-617-679-2616 EDUCATION: Residency in Neurology. Walter Reed Army Medical Center, Washington, D.C. Completed June, 1995. Ph.D. Johns Hopkins University School of Public Health and Hygiene, Baltimore, Maryland. Completed June, 1992. Advisor: Solomon H. Snyder, MD. M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland. Completed June 1991. B. S. (Zoology). University of Maryland, College Park, Maryland. Completed June 1984, Magna Cum Laude. CURRENT POSITION: Vice President, Neurology Drug Discovery and Development Center

a. Head, Experimental Medicine-Externalized (XMX) (November 2015-present) • Responsible for establishing and running a new research incubator aimed at novel

technology development in collaboration with external partners. • New IP generation • New spinout NewCo formation of XMX Bioscience b. Integrator, Neuropharmacology and Biomarkers (November 2015-present) • Scientific mentoring with Biomarker leads • Data review and scientific strategy consulting with Biomarker leads • Evaluation and the in-licensing of biomarker technologies c. Founder and Co-Director, Biogen-Mass General Hospital Anne B. Young Fellowship in Translational Neuroscience (2011-present) http://www.massgeneral.org/neurology/assets/Education/Anne%20B%20Young%20Neuroscience%20Translational%20Medicine%20Fellowship.pdf • A new paradigm in training the drug developers of the future

INDUSTRY ACTIVITIES OVER PAST 5 YRS: 1. Vice President, Clinical Development Sciences, Biogen Idec. July 2010-present.

a. Functional Area Head, Experimental Medicine (Jan 2011-Aug 2105)

• Responsible to developing and implementing company strategy for Neuroscience Biomarkers (Imaging, Electrophysiology, CSF, Cognitive testing, etc.)

• Strategic lead, Biogen’s molecular and functional imaging initiatives. • Responsible for recruiting and managing directors for Neurology clinical biomarker

development work. b. Therapeutic Area Head, Neurodegeneration (July 2010-June 2013) • Responsible for developing and executing clinical development strategy for

Neurodegeneration therapeutics (Alzheimer’s, Parkinson’s, ALS, Neuropathic Pain, Peripheral Neuropathy).

• Responsible for recommending key opportunities for business development and licensing of Neurodegeneration therapeutics.

• Responsible for recruiting and managing medical directors for all Neurodegeneration programs and assuring highest quality of clinical development plans and study protocols.

3. Vice President, Neuroscience & Ophthalmology (NSO), Novartis Pharmaceutical Corporation. June 2009-July 2010

a. Global Program Head: Pre-‘Proof of Concept’ • Key interface between Novartis Institute for Biomedical Research (NIBR) and

Clinical Development. • Responsible for clinical development plan for 2 Pre-‘Proof of Concept’ (PoC)

molecules including Ph2B clinical trial design and execution, Peri-PoC and Post-PoC enabling strategies, and methodologies.

• Developed framework for and oversaw NSO Franchise Clinical Development biomarker plan

• Represented Novartis on NIH and CAMD Neuroscience biomarker panels b. Business Development and Licensing Evaluation lead for Neuroscience • Co-developed licensing strategy for Neurodegeneration and Neuropsychiatry

disease areas • Supported due diligence work. c. U.S. site head for Global NSO Clinical Development Franchise

• Oversight and management of US East Hanover NJ Site personnel (n=60), site activities, and US budgets for Global NSO Franchise

3. Director, Neuroscience Experimental Medicine, Merck & Co, Inc. October 2006-June 2009

a. Neuroscience franchise Experimental Medicine (EM) lead • Responsible for developing short, mid, and long-term EM strategy for the

Neuroscience franchise • Responsible for developing, tracking and adhering to EM deliverables for

Neuroscience franchise objectives • Responsible for training and mentoring of other Neuroscience EM Clinical monitors

• Responsible for design, oversight, conduct, analysis, and presentation of neuroscience EM studies

• Early Development Team participation: Participated in 4 Merck drug development teams as Experimental Medicine representative

• Clinical Studies with direct medical monitoring responsibility • Guest Member, Neuroscience Franchise Coordinating Committee

o Responsible for providing EM perspective on Franchise strategy and in-licensing opportunities

o EM and biomarker strategy presentations to Senior Management • Member of translational Neuroscience biomarker working groups:

Electroencephalography, Cognition, Alzheimer’s Disease biomarkers, Cerebrospinal fluid dynamics and Blood Brain Barrier.

o Drove clinical translation of preclinical CNS efforts and developed SOPs for using biomarker platforms in early drug development decisions.

• Responsible for establishing and maintaining key external consultants for CNS biomarker development work and translational Neurosciences

b. Member, Merck Research Laboratories (MRL) Novel Technologies Research Licensing Committee • Co-chair of translational sciences working group • Responsible for identifying technology gaps in translational/clinical science across

Merck. • Identification, evaluation, and recommendation for in-licensing of novel

technologies to fill translational/clinical science gaps.

c. Co-leader, MRL India Phase 1 Project Team • Responsible for drafting and implementing Merck phase 1 research efforts in India

with specific focus on translational neuroscience and clinical pharmacology • Identification of key phase one clinical research sites and opinion leaders to work

with in India • Started 2 clinical studies in India d. Cross-franchise consultant on EM studies in cancer, obesity, pain and muscle biology

PROFESSIONAL ACADEMIC ACTIVITIES: Singularity University, Visiting Faculty since 2012 X Prize Foundation Innovation Board member; member of Neuroscience Visioneering Group since 2010 Neurologist; Board re-certification 2006-2016

Professor with Tenure, Department of Neurology, Department of Neuroscience, Department of Pathology, and Department of Anesthesiology, Uniformed Services University of the Health Sciences (USUHS). Adjunct Professor status since 2006. Staff Neurologist, Walter Reed Army Medical Center and National Naval Medical Center 1995-2006 Lt. Colonel, United States Army. Honorable Discharge, 2006 Course Director, Neurobiology of Disease. Neuroscience Program, USUHS. 1995-2006 USUHS Faculty Senator, 2001-2005 Chair, Research Committee of the USUHS Faculty Senate, 2001-2005 Member, USUHS Novel Technologies, Research and Licensing Committee, 2001-2006 Faculty Chair, USUHS University Space Committee, 2005-2006 President, Potomac Chapter of the Society for Neuroscience, 2003-2006 Member, Society for Neuroscience, since1986 Member, American Association of Neurology, since 1993 HONORS: Outstanding Graduate Educator Award, USUHS, 2006 Bailey K. Ashford Medal for Clinical Research, Walter Reed Army Medical Center, 1995 General Graves B. Erskine Award for Most Outstanding Clinical Resident, Walter Reed Army Medical Center, 1995 U.S. Army Commendation Medals, 1992, 1993, 1995 U.S. Army Neurology Resident Research Award, 1993 Delta Omega Public Health Honor Society – Johns Hopkins University School of Public Health and Hygiene, member since1992. Alpha Omega Alpha Medical Honor Society – Johns Hopkins University School of Medicine, member since1991. American Heart Association Research Fellowship, 1986–1987

U.S. Army Health Professions Scholarship, 1984–1986, 1988–1989, 1990–1991 Provost Scholar, Department of Zoology, University of Maryland, College Park, MD 1984 Mortar Board, University of Maryland, College Park, MD 1982-1984 LAST COMPLETED ACADEMIC RESEARCH FUNDING (Principal Investigator on all): “Oxygen sensing in human glioma cells” (RO1). Source: NIH/NINDS Last Period of support: 7/1/02-6/30/06, Funded continuously for 8 years. “Nutriceutical inhibition of neoplastic HIF (R21)”. Source: NIH/NCI Period of support: 1/1/06-12/31/07. “Metabolic Support for the Injured Nervous System”. Source: Defense Brain and Spinal Cord Injury Program, Department of Defense. Period of support: 1/1/03-3/31/06. “Changes in function of endoplasmic reticulum compartments in brain injury” Source: USUHS, Department of Defense. Period of support: 10/1/04-9/30/07, “Xenon Therapy in Controlled Cortical Impact-induced Traumatic Brain Injury”. Source: The Gemi Fund. Period of Support: 8/1/2005 – 7/31/2007. “PI3K Pathway Regulation of the HIF-1 Transcription factor in Cancer”. Source: U.S. Military Cancer Institute, Department of Defense. Period of Support: 7/1/05- 6/30/06. “Carbon Monoxide Hypoxia in Tobacco Smoke Induced Disease” Source: Flight Attendants Medical Research Institute (FAMRI) . Period of Support: 7/1/05-6/30/07. “Oxaloacetate induced activation of HIF-1”.Source: Humanetics Corporation CRADA Period of Support: 7/1/2005-6/30-2007. TRAINEES: Individuals mentored while in academia: 8 PhD dissertations, 12 postdoctoral fellows, 2 clinical fellows Individuals mentored as Director of Biogen-MGH Translational Neurology Fellowship: 2 graduates, 2 currently in training INVENTIONS AND PATENTS: (needs updating) 1. Wearable medical detector. WGS No. B1152.70063US00

2. Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases. Filed March, 2015, Application No. 62/136,431 3. A brain-computer interface test battery for the physiological assessment of nervous system health. WIPO Patent Application WO/2010/147913 4. Device and method to deplete A-beta from cerebrospinal fluid; WIPO Patent Application WO/2009/155538, filed 2008 5. Erythropoietin and Erythropoietin Receptor Expression in Human Cancer

US 7432051; US 20050260580 6. Activation of Hypoxia-Inducible Gene Expression

US 20070173545 7. Cellular Phosphorylation Potential Enhancing Compositions, Preparation and Use

Thereof. US 7358278; US20040147604 8. Methods for Lowering HIF-1 Mediated Gene Expression

US 20080045462

FOUNDER: BCI Medical, LLC; Brain Computer Interface for personalized brain health assessment, June 2009. PUBLICATIONS: A. PEER-REVIEWED ORIGINAL ARTICLES 1. Sevigny J, Suhy J, Chiao P, Cen T, Klein G, Purcell D, Oh J, Verma A, Sampat M,

Barakos J. Amyloid PET screening for enrichment of early stage Alzheimer’s disease clinical trial: Experience in a pahse 1b clinical trial. (in submission)

2. Morris A, Sharp M, N Albargothy N, Fernandes R, Hawkes C, Verma A, Weller RO,

Carare R. Vascular basement membranes as pathways for the passage of fluid into and out of the brain (in submission, Acta Neuropathologica)

3. Okkerse P, Hay JL, Versage E, Tang T, Galluppi G, Ravina B, Verma A, Williams L, Aycardi Groeneveld GJ. A randomized, blinded, placebo-controlled, multiple ascending dose study of the safety, tolerability, pharmacokinetics, and efficacy of BG00010 in patients with sciatica (in submission).

4. Wolf D, Hesterman JY, Sullivan JM, Orcutt KD, Silva MD, Lobo M, Wellman T, Hoppin J, Verma A. Dynamic dual isotope molecular Imaging elucidates principles for optimizing intrathecal drug delivery (in press; Journal of Clinical Investigation Insights), 2016

5. Chen L, Beckett A, Verma A, Feinberg DA. Dynamics of respiratory and cardiac CSF

motion revealed with real-time simultaneous multi-slice EPI velocity phase contrast imaging. Neuroimage Nov 15;122:281-7, 2015

6. Rapacchi S, Smith RX, Wang Y, Yan L, Sigalov V, Krasileva KE, Karpouzas G,

Plotnik A, Sayre J, Hernandez E, Verma A, Burkly L, Wisniacki N, Torrington J, He X, Hu P, Chiao PC, Wang DJ. Towards the identification of multi-parametric quantitative MRI biomarkers in lupus nephritis. Magn Reson Imaging. Nov;33(9):1066-74. , 2015

7. Ryan TE, Erickson ML, Verma A, Chavez J, Rivner MH, McCully KK. Skeletal muscle

oxidative capacity in amyotrophic lateral sclerosis. Muscle Nerve. Nov;50(5):767-74, 2014

8. Xing G, Ren M, Verma A. Divergent temporal expression of hyaluronan metabolizing

enzymes and receptors with craniotomy vs. controlled-cortical impact injury in rat brain: a pilot study Front. Neurol., Sep 11;5:173. 2014

9. Watson WD, Buonora JE, Yarnell AM, Lucky JJ, D'Acchille MI, McMullen DC, Boston

AG, Kuczmarski AV, Kean WS, Verma A, Grunberg NE, Cole JT. Impaired cortical mitochondrial function following TBI precedes behavioral changes. Front Neuroenergetics. Feb, 5:12, 2014

10. Ghorbanian P, Devilbiss DM, Verma A, Bernstein A, Hess T, Simon AJ and HASHEM Asharafiuon H. Identification of Resting and Active State EEG Features of Alzheimer’s Disease using Discrete Wavelet Transform. Ann Biomed Eng. Jun;41(6):1243-57, 2013

11. McMullen DC, Kean WS, Verma A, Cole JT, and Watson WD. A microplate technique

to simultaneously assay calcium accumulation in endoplasmic reticulum and SERCA release of inorganic phosphate Biological Procedures 14:4, 2012

12. Xing, G, Ming R, O’Neill JT, Sharma P, Verma A, Watson W. Pyruvate

dehydrogenase phosphatase 1 mRNA regulation in rat brain regions after traumatic brain injury. Neurosci. Lett 535(2): 140-5, 2012

13. Cole JT, Kean WS, Pollard HB, Verma A, Watson W, Glucose-6-phosphate reduces

calcium accumulation in rat brain endoplasmic reticulum. Front Mol Neurosci, 5:51, 2012

14. Xing G, Ren M, O'Neill JT, Watson WD, Verma A. Controlled cortical impact injury

and craniotomy result in divergent alterations of pyruvate metabolizing enzymes in rat brain. Exp Neurol Mar; 234(1):31-8, 2012

15. Cole JT, McMullen DC, Kean WS, Yarnell AM, Lucky JJ, Selak MA, Buonora JE,

Grunberg NE, Verma A, Watson WD. Manipulating thyroid status alters endoplasmic

reticulum calcium homeostasis in rat cerebellum. Indian J Exp Biol. 50(1):7-18, 2012 16. Cho W, Maruff P, Connell J, Gargano C, Calde N, Doran S, Fox-Bosetti S, Hassan A,

Renger J, Verma A. Additive effects of acetylcholinesterase inhibition and histamine H3 receptor inverse agonist in overcoming scopolamine-induced cognitive impairment in healthy young adults. Psychopharmacology 218(3):513-24, 2011

17. Halim ND, McFate T, Mohyeldin A, Okagaki P, Korotchkina LG, Patel MS, Jeoung NH,

Harris RA, Schell MJ, and Verma A. Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and Neurons. Glia Aug; 58(10):1168-76, 2010

18. Ozaki H, Zoghbi SS, Hong J, Verma A, Pike VW, Innis RB, Fujita M. In Vivo Binding of

Protoporphyrin IX to Rat Translocator Protein Imaged with Positron Emission Tomography. Synapse Aug;64(8):649-53, 2010

19. Cole JT, Mitala CM, Kundu S, Verma A, Elkind JA, Nissim I, Cohen AS. Dietary

branched chain amino acids ameliorate injury-induced cognitive impairment. Proc Natl Acad Sci U S A. Jan 5; 107(1):366-71, 2010

20. Xing G, Ren M, Watson WA, O'Neil JT, Verma A. Traumatic brain injury-induced

expression and phosphorylation of pyruvate dehydrogenase: a mechanism of dysregulated glucose metabolism. Neurosci Lett. Apr 17;454(1):38-42, 2009

21. Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations

contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res. Jan 15;15(2):476-84, 2009

22. Jiang X, Xing G, Yang C, Verma A, Zhang L, Li H. Stress Impairs 5-HT(2A) Receptor-

mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology. Jan;34(2):410-23, 2009

23. Huicho L, Xing G, Qualls C, Rivera-Ch M, Gamboa JL, Verma A, Appenzeller O.

Abnormal energy regulation in early life: childhood gene expression may predict subsequent chronic mountain sickness. BMC Pediatr. Oct 27;8:47, 2008

24. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, Wu H, Schell MJ,

Tsang TM, Teahan O, Zhou S, Califano JA, Jeoung NH, Harris RA, Verma A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008 Aug 15;283(33):22700-8, 2008

25. Xing G, Qualls C, Huicho L, River-Ch M, Stobdan T, Slessarev M, Prisman E, Ito S,

Wu H, Norboo A, Dolma D, Kunzang M, Norboo T, Gamboa JL, Claydon VE, Fisher J, Zenebe G, Gebremedhin A, Hainsworth R, Verma A, Appenzeller O. Adaptation and mal-adaptation to ambient hypoxia; Andean, Ethiopian and Himalayan patterns. PLoS

ONE. Jun 4;3(6):e2342. 2008 26. Halim ND, Lipska BK, Hyde TM, Deep-Soboslay A, Saylor EM, Herman MM, Thakar

J, Verma A, Kleinman JE. Increased lactate levels and reduced pH in postmortem brains of schizophrenics: Medication confounds. J Neurosci Methods. 169(1): 208-13, 2008.

27. Mohyeldin A, Dalgard CL, Lu H, Mcfate T, Tait AS, Patel VC, Wong K, Rushing E,

Roy S, Acs G, Verma A. Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg. 106(2):338-50, 2007

28. Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani SK,

Chatterjee A, Koch W, Westra WH, Maitra A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A. 104(18):7540-5, 2007

29. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation

of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem. 280(51):41928-39, 2005

30. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Bell A, Verma A.

Erythropoeitin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol. 99(3):571-7, 2005

31. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A. Erythropoietin

signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7(5):537-43, 2005

32. Watson WD, Srivastava M, Leighton X, Glasman M, Faraday M, Fossam LH, Pollard

HB, and Verma A. Annexin 7 mobilizes calcium from endoplasmic reticulum stores in brain. Biochim Biophys. Acta 1742(1-3):151-60, 2004

33. Dalgard C, Lu H, Mohyeldin A, and Verma A. Endogenous 2-oxoacids regulate

expression of oxygen sensors. Biochem J. 380(2):419-24, 2004 34. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A,

Lwin A, Colegial C, Allman JM, Schiffmann R. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 82(3):192-207, 2004.

35. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin

expression in human endometrial carcinoma. Cancer. 100(11):2376-86, 2004 36. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. Autocrine erythropoietin signaling

inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett. 214(2):243-51, 2004

37. Loh Y, Watson WD, Verma A, Chang ST, Stocker DJ, Labutta RJ. Acute Wernicke's

encephalopathy following bariatric surgery: clinical course and MRI correlation. Obes. Surg. 14(1):129-32, 2004

38. Watson WD, Facchina SL, Grimaldi M, Verma A. Sarco-endoplasmic reticulum Ca2+

ATPase (SERCA) inhibitors identify a novel calcium pool in the central nervous system. J Neurochem. 87(1):30-43, 2003

39. Grimaldi M, Maratos M, Verma A. Transient receptor potential channel activation

causes [Ca 2+]i oscillations and is not involved in capacitative Ca 2+ entry in glial cells. J Neurosci. 23(11): 4737-45. 2003

40. Watson WD, Verma A, Lenart MJ, Quast TM, Gauerke SJ, McKenna GJ. MRI in acute

Wernicke's encephalopathy. Neurology. 61(4):527. 2003 41. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma

A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 162(6):1789-806, 2003

42. Eccles TG, Patel A, Verma A, Nicholson D, Lukes Y, Tuttle RM, Francis GL.

Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator. Ann Clin Lab Sci. 33(4):411-22. 2003

43. Lu H, Forbes A, and Verma A Hypoxia-inducible Factor 1 Activation by Aerobic

Glycolysis Implicates the Warburg Effect in Carcinogenesis. J. Biol. Chem. 277(26):23111-5, 2002

44. Acs G, Zhang, PJ, Rebbeck, TR, Acs, P, and Verma, A Immunohistochemical

expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95(5):969-81, 2002

45. Acs, G. , Acs, P., Beckwith, S., Pitts, r., Clements, E., Wong, K., and Verma, A.,

Erythropoietin and erythropoietin receptor expression in human cancer Cancer Res 61(9):3561-5, 2001.

46. Pieper AA, Walles T, Wei G, Clements EE, Verma A, Snyder SH, and Zweier JL.

Myocardial Postischemic Injury is Reduced by Poly ADP-ribose Polymerase-1 Gene Disruption. Mol. Med. 6(4):271-82, 2000.

47. Pieper AA, Blackshaw S, Clements EE, Brat DJ, Krug DK, White AJ, Pinto-Garcia P,

Favit A, Conover JR, Snyder SH, and Verma A. Poly(ADP-ribosyl)ation Basally Activated by DNA Strand Breaks Reflects Glutamate-Nitric Oxide Neurotransmission. Proc. Natl. Acad. Sci. USA 97(4):1845-50, 2000.

48. LaPlaca, M. C., Raghupathi, R., Verma, A., Pieper, A. A., Saatman, K. E., Snyder, S.

H., and McIntosh, T.K. Temporal Patterns of Poly(ADP-ribose) Polymerase Activation in the Cortex Following Experimental Brain Injury in the Rat. J. Neurochem 73:205-213, 1999.

49. Pieper, A. A., Brat, D.M., Krug, D. K., Watkins, C. C., Gupta, A., Blackshaw, S.,

Verma, A., Wang, Z-Q., and Snyder, S.H. Poly(ADP-ribose) Polymerase Deficient Mice are Protected from Streptozotocin-Induced Diabetes. Proc. Natl. Acad. Sci. USA 96:3059-3064, 1999.

50. Verma, A., Hirsch, D., Song S–Y., Dilahey, L., Williams, J., and Snyder, S.H.;

Photodynamic Therapy: Mitochondrial Benzodiazepine Receptors as Therapeutic Targets. Molecular Medicine 4:40-45, 1998.

51. Abdelrahim, M., Morris, E., Carver, J., Facchina, S., and Verma, A. Liquid

Chromatographic Assay of Dityrosine in Human Cerebrospinal Fluid. J. Chromatography B 696:175-182, 1997.

52. Jing, M, Bina, S., Verma, A., Hart, J. and Muldoon, S. Effects of Halothane and

Isoflurane on Carbon Monoxide-Induced Relaxations in the Rat Aorta. Anesthesiology 85:347-354, 1996.

53. McEnery, M.W., Dawson, T.M., Verma, A., Gurley, D., Colombini, M., and Snyder,

S.H. Mitochondrial Voltage-Dependent Anion Channel: Immunochemical and Immunohistochemical Characterization in Rat Brain. J. Biol. Chem. 268:23289-96, 1993.

54. Verma, A., Hirsch, D.J., Glatt, C., Ronnet, G.V. and Snyder, S.H. Carbon Monoxide: A

Putative Neural Messenger. Science 259:381–384, 1993. 55. Verma, A., Hirsch, D.J. and Snyder, S.H.; Calcium Pools Mobilized by Calcium or

Inositol 1,4,5–Triphosphate are Differentially Localized in Rat Brain. Mol. Biol. Cell 3:621–631, 1992.

56. Miller, K.K., Verma, A., Snyder, S.H. and Ross, C.A.; Localization of an Endoplasmic

Reticulum Calcium ATPase mRNA in Rat Brain by In Situ Hybridization. Neuroscience 43:1–9, 1992.

57. Verma, A., Hirsch, D.J., Hanley, M.R., Thastrup, O. Christensen, S.B. and Snyder,

S.H. Inositol Triphosphate and Thapsigargin Discriminate Endoplasmic Reticulum Stores of Calcium in Rat Brain. Biochem. Biophys. Res. Comm. 172:811– 816, 1990.

58. Verma, A., Ross, C.A., Verma, D., Supattapone, S.S. and Snyder, S.H. Rat Brain

Endoplasmic Reticulum Calcium Pools are Anatomically and Functionally Segregated. Cell Regulation 1:781–790, 1990.

59. Mourey, R.J., Verma, A., Supattapone, S.S. and Snyder, S.H. Purification and

Characterization of the Inositol 1,4,5–Triphosphate Receptor Protein from Vas Deferens. Biochem. J. 272:383–389, 1990.

60. Hwang, P.M., Verma, A., Bredt, D.S. and Snyder, S.H. Localization of

PhosphoinositideSignaling Components in Rat Taste Cells: Role in Bitter Taste Transduction." Proc. Natl. Acad. Sci., USA 87:7395–7399, 1990.

61. Verma, A., and Snyder, S.H. Characterization of Porphyrin Interactions with

Peripheral Type Benzodiazepine Receptors. Mol. Pharmacol. 34:800–805, 1988. 62. Snyder, S.H., Verma, A. and Trifilletti, R.R. The Peripheral Type Benzodiazepine

Receptor: A Protein of Mitochondrial Outer Membranes Utilizing Porphyrins as Endogenous Ligands. Faseb J. 1:282–288, 1987.

63. Verma, A., Nye, J.S. and Snyder, S.H. Porphyrins are Endogenous Ligands for the

Mitochondrial (Peripheral Type) Benzodiazepine Receptor. Proc. Natl. Acad. Sci, USA 84:2256– 2260, 1987.

64. Verma, A., Houston, M. and Marangos, P.J. Solubilization of an Adenosine Uptake

Site in Brain. J. Neurochem. 45:596–603, 1985. 65. Verma, A. and Marangos, P.J. Nitrobenzylthioinosine Binding in Brain: An

Interspecies Study. Life Sci. 36:283–290, 1985. 66. Marangos, P.J., Finkel, M.S., Verma, A., Matari, M.F., Patel, J. and Patterson, R.E.

Adenosine Uptake Sites in Dog Heart and Brain: Interactions with Calcium Antagonists. Life Sci. 35:1109–1116, 1984.

67. Patel, J., Marangos, P.J., Heydorn, W.E., Chang, G., Verma, A. and Jocobowitz, D.

S–100–Mediated Inhibition of Brain Protein Phosphorylation. J. Neurochem. 41:1040–1045, 1983.

B. REVIEWS, BOOK CHAPTERS, COMMENTARIES: 1. Hargreaves R, Hoppin J, Sevigny J, Patel S, Chiao P, Klimas M, Verma A. Optimizing

central nervous system drug development using molecular imaging. Clin Pharmacol Ther Jul;98(1):47-60. doi: 10.1002/cpt.132. Review. 2015

2. Verma A, DeClercq R, Achten E. Incorporating functional MRI into clinical pharmacology trials; in: Imaging in CNS Drug Discovery and Development edited by David Borsook, Lino Becerra, Edward Bullmore and Richard Hargreaves. 2009 (ISBN: 978-1-4419-0133-0). 2008

3. Verma, A. Oxygen-sensing in tumors. Curr Opin Clin Nutr Metab Care. Jul;9(4):366-

78. 2006 4. Verma A, “Low-Tech” neuroprotection for traumatic brain injury. J Head Trauma

Rehabil. 16(2):206-9, 2001 5. Verma A. Opportunities for Neuroprotection in Traumatic Brain Injury. J. Head Trauma

Rehabil. 15(5):1149-61, 2000. 6. Henke M, Verma A, Acs G. Erythropoietin receptors on cancer cells: exciting

perspectives, difficult to appreciate. Blood. 108(3):1107-8, 2006

7. Verma A. Alzheimer's: No Pain or No Complain? Psychiatry 63(1):13-5, 2000. 8. Pieper, A. A., Verma. A., Zhang, J., and Snyder, S. H. Poly(ADP-ribose) Polymerase,

Nitric Oxide, and Cell Death. Trends Pharmacol. Sci. 20:171-181, 1999. 9. Snyder, S.H., McEnery, M.W. and Verma, A. Molecular Mechanisms of Peripheral

Benzodiazepine Receptors. Neurochem. Res. 14:119–123, 1989. 10. Verma, A. and Snyder, S.H. Peripheral Benzodiazepine Receptor. Ann. Rev.

Pharmacol. Toxicol. 29:307–22, 1989. C. ABSTRACTS: 1. Amyloid PET screening results by APOE ε4 status from a Phase 1b clinical study

evaluating BIIB037 in prodromal to mild AD patients (Ping Chiao, Joyce Suhy, Jerry Barakos, Meredith Burke, Greg Klein, Ajay Verma, and Jeff Sevigny) AAIC 2013

2. Amyloid PET screening results by APOE ε4 status from a Phase 1b clinical study

evaluating BIIB037 in prodromal to mild AD patients (Ping Chiao, Joyce Suhy, Jerry Barakos, Meredith Burke, Greg Klein, Ajay Verma, and Jeff Sevigny) CTAD 2013

3. Amyloid PET screening results by APOE ε4 status from a Phase 1b clinical study evaluating BIIB037 in prodromal to mild AD patients (Ping Chiao, Joyce Suhy, Jerry Barakos, Meredith Burke, Greg Klein, Ajay Verma, and Jeff Sevigny) HAI 2014

4. Amyloid PET Screening for Enrollment into Alzheimer’s Disease Clinical Trials: Initial Experience in a Phase 1b Clinical Trial (Sevigny Jeff, Suhy Joyce, Chiao Ping, Klein Gregory, Oh Joonmi, Purcell Derk, Verma Ajay, Sampat Mehul, Barakos Jerome) HAI 2014

5. Development and Evaluation of Multi-Modality Renal Functional MRI (Stanislas Rapacchi, Robert X. Smith, Yi Wang, Lirong Yan, Victor Sigalov, Ping Chiao, Ajay Verma, Linda Burkly, Nicolas Wisniacki, Jaime Torrington, Xiang He, Peng Hu, and Danny JJ

Wang) ISMRM 2014

6. Amyloid PET screening results by APOE ε4 status from a Phase 1b clinical study evaluating BIIB037 in prodromal to mild AD patients (Ping Chiao, Joyce Suhy, Jerry Barakos, Meredith Burke, Greg Klein, Ajay Verma, and Jeff Sevigny) CTAD 2013

7. Coimbra A., Feng D, Apreleva S, Hu P, Ramana S, Bernstein A, Guenther M, Cho W, Forman M, Verma A, Herman G, Baumgartner R, and Feinberg D. Test-Retest Reproducibility Assessment of CBF Measurements with 3D GRASE ASL at 1.5T in Aged Population. ISMRM Program 36560, 2011

8. Kea W, Cole JT, McMullen DC, Verma A, Campbell W, Watson WD. Elevated myoplasmic glucose-6-phosphate: A novel intracellular mechanism underlying exertional rhabdomyolysis, Society for Neuroscience Program No. 669.20, 2011

9. Lucky J, McMullen DC, Kean A, Verma A, Cole JT, Watson. A technique to quantify

coupling of endoplasmic reticulum calcium accumulation with release of inorganic phosphate. Society for Neuroscience Program No. 669.18, 2011

10. Watson WD. McMullen WS, Kean A, Verma A, Cole JT. Glucose-6-phosphate

selectively decreases calcium accumulation in rat brain endoplasmic reticulum. Society for Neuroscience Program No. 669.19, 2011

11. Hoppin J, Hesterman KD, Orcutt KD, Cupelo W, Germino M, White E, Lackas C, Lane

M, Kentala D, Reinfield T, Pickel K, Verma A. Assessing pharmacokinetics of intrathecally injected 111In-DTPA and 18F-FDG via in vivo imaging in rats. Society for Neuroscience Program No. 519.14, 2011

12. Heidegger T, Verma A, Moller C, Struyck A, Ziemann U. TMS and qEEG provide

potential biomarkers of pharmacological modulation of the NMDA receptor in human cerebral cortex Society for Neuroscience Program No. 881.3, 2010

13. Stopa EG, Nikonova EV, Podtelezhnikov AA, Tanis, KQ, Finney EM, Stone DJ,

Camargo LM, Parker L, Verma A, Baird A, Miller MC, Donahue JE, Gonzales A, Eliceiri B, Silverberg GD, Klinge PM, Johansen CE. Gene expression profiling of choroid plexus in Alzheimer’s disease reveals important implications of CSF dynamics. Society for Neuroscience Program No. 424.3, 2010

14. McFate T, Mohyeldin A, Halim N, Wu H, Schell M, Lu H, Verma A; PDH E1α

phosphorylation correlates with aerobic glycolysis in gliomas and other human cancers Society for Neuroscience Program No. 389.7. 2006

15. Henriques J, Mcfate T, Ren M, Xing A, Mohyeldin A, Verma A; Branched-chain amino

acids activate hypoxia inducible factor-1α and stimulate vascular endothelial growth factor expression in glioma cells Program No. 566.5. 2006

16. Xing G, Ren M, McFate T, Verma A; Injury induced expression of pyruvate dehydrogenase phosphatase (PDP1) reveals neuroprotective plasticity of brain energy metabolism. Society for Neuroscience Program No. 181.2. 2006

17. Mohyeldin A, McFate T, Halim, H, Wu H, Schell M, Lu H, Verma A; PDK-1 expression

regulates aerobic glycolysis and hypoxic survival of cancer cells: molecular basis for the “Warburg Effect” Society for Neuroscience Program No. 729.15. 2006

18. Dalgard CL, Lu H, Verma A. Differential regional expression of HIF prolyl hydroxylase

mammalian oxygen sensors in rat brain Society for Neuroscience Program No. 199.3. 2004

19. Mohyeldin A, Lu H, Dalgard CL, Fatakdawala M, Acs G, Verma A. Hypoxia-inducible

erythropoietin signaling promotes invasiveness of human cancers Society for Neuroscience Program No. 462.1. 2004

20. McFate TJ, Dalgard CL, Lu H, Mohyeldin A, Verma A. Normoxic regulation of a green

fluorescent protein construct containing the HIF-1 oxygen dependant degradation domain. Society for Neuroscience Program No. 462.2. 2004

21. Lu H, Dalgard CL, Mohyeldin A, Verma A. Regulation of HIF prolyl hydroxylase by 2-

oxoacids and amino acids. Society for Neuroscience Program No. 462.15. 2004 22. Dalgard CL, Mohyeldin A, Lu A, Pandipati S, Verma A. Oxygen sensors in the brain.

Society for Neuroscience Program No. 101.4. 2003 23. Lu H, Mohyeldin A, Dalgard CL, Verma A. Pyruvate metabolites activate HIF-1

mediated gene expression. Society for Neuroscience Program No. 101.16. 2003 24. Mohyeldin A, Lu H, Dalgard CL, Verma A. In vitro and in vivo regulation of HIF-1 by 2-

oxoacids. Society for Neuroscience Program No. 101.19. 2003 25. Ventra C, Grimaldi M, Verma A. Differential calcium handling in type 1 astrocytes and

c6 astrocytoma cells: possible role of SERCA in glial cell transformation. Society for Neuroscience Program No. 378.13. 2003

26. McFate T, Favit A, Grimaldi M, Verma A. Synergistic neuroprotection by nutriceuticals.

Society for Neuroscience Program No. 638.5. 2003 27. Grimaldi M, Watson WD, Maratos M, Verma A. Defect of inositol trisphosphate

receptor function in U-87 mg human glioma cells. Society for Neuroscience Program No. 691.8. 2003

28. Grimaldi M, Maratos M, Verma A. Native diacylglycerol-sensitive transient receptor

potential channels cause cytosolic calcium oscillations upon activation but are not

involved in store-activated calcium entry in glial cells. Society for Neuroscience Program No. 437.13. 2002

29. Watson WD, Srivastava M, Pollard H, Verma A. Selective loss of IP3-sensitive

calcium pools in annexin-7 +/- mouse brain. Society for Neuroscience Program No. 436.2. 2002

30. Maratos M, Grimaldi M, Verma A. HIF-1 activation by hypoxia in human glioma cells

does not require cytosolic calcium elevation or pkc membrane translocation. Society for Neuroscience Program No. 694.17. 2002

31. Mohyeldin A, Liu S, Lu H, Dalgard C, Verma A. Hypoxia enhances cell survival in

human glioma cells Program No. 718.6. 2002 32. Lu H, Forbes RA, Verma A. A novel glycolytic signaling mechanism regulates

hypoxia-inducible transcription factor 1 (HIF-1) independently of hypoxia. Society for Neuroscience Program No. 718.7. 2002

33. Dalgard CL, Lu H, Liu S, Mohyeldin A, Verma A. Mitochondrial electron transport

chain inhibitors block HIF-1 accumulation in human glioma cells: potential inhibitory role for reactive oxygen species in hypoxic signaling. Society for Neuroscience Program No. 718.8. 2002

34. Mohyeldin, A., Liu, S., lu, H., Dalgard, A., Wong, A., and Verma, A. Erythropoietin

signaling promotes survival of human gliomas. Accepted for oral presentation at 78th Annual Meeting of the American Association of Neuropathologists, Denver, CO, June 20 - 23, 2002

35. Dalgard, C.L., Beckwith, S., Pandipati, S., Verma, A., Mitochondrial benzodiazepine

receptors regulate porphyrin synthesis, accumulation, and photodynamic cell killing in human glioma cells. Mol. Biol. Cell. 12S: 385a, 2001

36. Verma, A. and Grimaldi, M. Altered capacitative calcium entry in human glioma cells.

Society for Neuroscience Abstr 2000 37. Cohen, N.A., LIU, S., Lu, h., Friedman, J., Shaungshoti, S., Tong-Hui Mixon, H.,

Wong, K., Verma, A. Erythropoietin and erythropoietin receptor expression in human gliomas. Society for Neuroscience Abstr, 2000

38. Watson, W., Williams, L., Lu, M., Zhang, J., and Verma, A. “A novel rat brain calcium

pool is rapidly recruited for calcium buffering following ischemia-reperfusion injury.” Society for Neuroscience Abstr., 2000

39. Watson, W., Acs, P., Facchina, S., Ferrera, D., and Verma, A. “A novel rat brain

calcium pool enriched in brainstem and spinal cord injury.” Society for Neuroscience Abstr., 2000

40. Cohen, N.A., Forbes, A., Acs, P., Haigney, M., Cohen, A.S., and Verma, A. “Oxygen

signaling in human glioma cells involves H2O2-sensing potassium channels.” Society for Neuroscience Abstr., 2000

41. Favit, A. and Verma, A. "Pyruvate protects neurons from H202, calcium and

glutamate toxicity" Society for Neuroscience Abstr. 29: 521.7, 1999 42. Verma, A., Butler, N., Augustus, N., Delgado, A., Facchina, S., and Beckwith, S.

"Mitochondrial benzodiazepine receptors: Role in porphyrin biosynthesis and photodynamic tumor therapy." Society for Neuroscience Abstr. 29: 716.7, 1999

43. Watson, W., Cai, D., Frerichs, K., Hallenbeck, J., and Verma, A. " [35S]GTP-gamma-

S binding and [45Ca2+] transport activities in the thirteen-lined ground squirrel (Spermophilustride cemlineatus) brain section remain sensitive to a agonist regulation during hibernation. Society for neuroscience Abstr. 29: 747.17, 1999.

44. Forbes, A., Favit, A., Beckwith, S., and Verma, A. “Hif-1 activation by hypoxia and

catalase involves protein kinase C activity”. Society for Neuroscience Abstr. 28: 89.1, 1998

45. Pieper, A., Blackshaw, S., White, A., Garcia-Pinto, P., Snyder, S., and Verma, A.

“Basal localized DNA turnover and poly(ADP-ribose)polymerase in brain reflect glutamate-nitric oxide transmission” Society for Neuroscience Abstr. 28: 569.13, 1998.

46. Brat, D., Pieper, A., Watkins, C., Blackshaw, S., Snowman, A., Wang, Z-Q., Verma,

A., and Snyder, S. “Poly(ADP-ribose)polymerase knockout mice are protected from streptozotocin-induced hyperglycemia and pancreatic islet cell loss” Society for Neuroscience Abstr. 28: 569.14, 1998

47. Lautar, S., Pieper,A., Verma, A., Lu, X., Zang, T., Liu, W., Li, J., Snyder, S., and

Zhang, J. “Post-ischemia treatment with GPI 6150 diminishes Poly(ADP-ribose)accumulation during ischemia-reperfusion injury in rat brain” Society for Neuroscience Abstr. 28: 480.16, 1998

48. Cortes, C., White, A., Watson, W., Pieper, A., Thomas, J., Auker, C., Ahlers, S.,

Verma, A. “Activation of the rat brain poly(ADP-ribose) Polymerase (PARP) by exposure to hyperbaric oxygen (HBO2)” Society for Neuroscience Abstr. 27: 856.4, 1997

49. Pieper, A., Blackshaw, S., Garcia-Pinto, P., White, A., Snyder, S., and Verma, A.

“Poly(ADP-ribose) Polymerase activation in vivo in Ischemia-reperfusion injury” Society for Neuroscience Abstr. 27: 846.15, 1997

50. Forbes, A., White, A., and Verma, A. “Hypoxia signaling pathway in human glioma

cells” Society for Neuroscience Abstr. 27: 652.9, 1997

51. Eliasson, M., Sampei, K., Mandir, A., Hurn, P., Traystman, R., Pieper, A., Verma, A.,

Wang, Z-Q., Dawson, T., Snyder, S., and Dawson, V. “Poly(ADP-ribose) synthetase knockout mice are resistant to cerebral ischemia” Society for Neuroscience Abstr. 27: 547.6, 1997

52. Forbes, A., Harris, P., Facchina, S., Vaidya, S., Verma, A. “Hypoxia sensing

mechanisms in human glioma cells” Society for Neuroscience Abstr. 26: 560.8, 1996 53. Cortes, C., Shea, P., Ahlers, S., Auker, C., verma, A., Elayan, I., and Schrot, J.

“Measurement of dityrosine after exposure to hyperbaric oxygen (HBO) and chronic administration of corticotrophin releasing factor (CRF)” Society for Neuroscience Abstr. 26: 750.15, 1996

54. Facchina, S. and Verma,A. “Selective Anion Permeabilities distinguish subcellular

calcium pools in rat brain” Society for Neuroscience Abstr. 25: 798.5, 1995 55. Facchina, S., Carver, J. and Verma, A. “Peroxynitrite generates dityrosine in human

cerebrospinal fluid” Proc. SEBM, 207, 301, 1995 56. Carlson, G., Carver,J., Erickson,M., Facchina, S., and Verma, A. “Free radical

tyrosine oxidation is regulated by tyrosine phosphorylation and serves as a clinical marker.” Neurology 45(Suppl. 4) #789S, p. A380, 1995

57. Lee, S., Facchina, S. and Verma, A. “Ischemia-reperfusion injury enhances

sarcoplasmic reticulum calcium transport in rabbit hearts” Proc. SEBM, 207, 302, July 1995

58. Carlson, G., Facchina, S., and Verma, A..“Neutrophil activation generates dityrosine,

a fluorescent bio-marker in human cerebrospinal fluid” Proc. SEBM, 207, 300, July 1995

59. Carlson, G., Carver, J., Erickson, M., Facchina, S., and Verma, A. “Tyrosine

phosphorylation serves a protein antioxidant role” Society for Neuroscience Abstr. 25: 298.24, 1995

60. Haney, J., Forbes, R., Srivastava, S., and Verma, A. “Neuronal localization of the dbl

gene product” Society for Neuroscience Abstr. 25: 346.11, 1995 61. Forbes, R., Haney, J. Siren, A-L., and Verma, A.” Hypoxia-inducible factor 1 as a

mediator of adaptive responses to hypoxia in NG108 cells” Society for Neuroscience Abstr. 25: 391.8, 1995

62. Verma, A., Erickson, M., Carver, J., and Carlson, G. Dityrosine as a monitor for free

radical mediated protein oxidation in human cerebrospinal fluid. Society for Neuroscience Abstr. 24: 641, 1994

63. Verma, A., Hirsch, D.J. and Snyder, S.H. "Glucose–6–phosphate modulates

regionally specific endoplasmic reticulum calcium pools in rat brain." Society for Neuroscience Abstr. 18:812, 1992

64. Hirsch, D.J., Verma, A., Glatt, C., Ronnett, G. and Snyder, S.H. "Carbon monoxide as

a physiological messenger indicated by heme oxygenase localization and cyclic GMP regulation." Society for Neuroscience Abstr. 18:1004, 1992

65. Verma, A., Hirsch, D.J., Dawson, T., Glatt, C. and Snyder, S.H. "Fluctuation of rat

brain calcium pools in kainic acid induced limbic seizure status." Society for Neuroscience Abstr. 17:350, 1991

66. Hirsch, D.J., Verma, A. and Snyder, S.H.; "Calcium induced calcium release is

demonstrated in rat and chicken brain microsomes." Society for Neuroscience Abstr. 17:350, 1991

67. McEnery, M.W., Dawson, T., Verma, A. and Snyder, S.H. "Intracellular channels: The

voltage dependent anion channel (VDAC) of rat brain mitochondria: Characterization and immunohistochemical localization." Society for Neuroscience Abstr. 17:1520, 1991

68. Verma, A. and Snyder, S.H. "Localization of two functionally distinct non–

mitochondrial calcium pools in rat brain." Society for Neuroscience Abstr. 16:629, 1990

69. Verma, A. and Snyder, S.H. "Distribution of two distinct calcium pools in rat brain."

Society for Neuroscience Abstr. 16, 1990 70. Verma, A. and Snyder, S.H. "Localization of cisplatin stimulated calcium uptake by

renal endoplasmic reticulum: A biomarker for palatinate toxicity." The Toxicologist 10:524, 1990

71. Verma, A., Ross, C.A., Supattapone, S., Verma, D. and Snyder, S.H.

"Autoradiographic visualization of inositol–1,4,5–triphosphate (IP3) sensitive calcium pools in rat brain." Society for Neuroscience Abstr. 15:658, 1989

72. Ross, C.A., Verma, A., Milner, T., MacCumber, M.W., Supattapone, S., Meldolesi, and

Snyder, S.H. "Phosphoinositide (PI) second messenger markers in rat cerebellar Purkinje cells." Society for Neuroscience Abstr. 15:657, 1989

73. Hwang, P.M., Verma, A., Bredt, D.S., Verma, D. and Snyder, S.H. "Evidence for Ins

(1,4,5) P3 as a second messenger in rat taste receptor cell signal transduction." Society for Neuroscience Abstr. 15:752, 1989

74. Supattapone, S., Verma, A., Ross, C.A. and Snyder, S.H. "Regional distribution of a non–mitochondrial, ATP + Mg2+ dependent calcium uptake pool in rat brain and peripheral tissues." Society for Neuroscience Abstr. 14:82, 1988

75. Atlas, S.J., Verma, A., Dharmarajan, A.M., Snyder, S.H. and Wallach, E.E"Peripheral

benzodiazepine receptors in the rabbit ovary: Correlation with luteinization." Serono Symposia, USA 1988

76. Verma, A., Trifilletti, R.R., Michael, E.M. and Snyder, S.H. "Peripheral type

benzodiazepine receptor: Isolation from outer mitochondrial membrane: Porphyrins as endogenous ligands: Hormonal Associations." Society for Neuroscience Abstr. 13:965, 1987

77. Trifiletti, R.R., Verma, A. and Snyder, S.H. “Molecular identification of "peripheral–

type" benzodiazepine receptors associated with outer mitochondrial membranes.” Society for Neuroscience Abstr. 12:666, 1986

78. Finkel, M.S., Marangos, P.J., Verma, A., Maturi, M.F., Patel, J. and Patterson, R.E.

"Calcium channels and adenosine uptake in dog heart and brain." The American Heart Association's 57th Scientific Sessions 1984

SEMINARS and SCIENCE CONFERENCE PANELS: Videos: 1. Big data in Neuroscience healthcare: http://www.youtube.com/watch?v=5CNRXfFCBIQ&feature=share&list=PL055Epbe6d5 Yqkkuc_rVrAcY4MQ19NRHD 2. Death's Design: http://vimeo.com/56707920 3. Cell Death: http://www.thedoctorschannel.com/view/cell-death/collection/futuremed-2012/ (alternate link: http://futuremed2020.com/ajay-verma-at-futuremed) 4. Brain Tech Israel 2013: How Neurotech will change our lives: https://www.youtube.com/watch?v=goys3-qni6w Invited talks: 1. CNS Summit, Boca Raton, October 2015 2. Centennial of the Burke Rehabilitation and Research Center, October, 2015 3. World Molecular Imaging Congress, Annual meeting in Honolulu, September 2015 4. World Medical Innovation Form, MGH, Boston, March, 2015 5. International Society of CNS Drug Development, Annual meeting Las Vegas, April 2014 6. FutureMed Conference, San Diego, Keynote talk, November 2013

7. Brain Tech Israel, Tel Aviv. Keynote talk, October 2013 8. FutureMed 2013, Singularity University, February 2013 9. StrataRx Conference on Big Data in Healthcare. Keynote speaker, October 2012 10. MSG (Muscle Study Group) Annual meeting, September 2012 11. Mass General Institute of Neurodegenerative Disorders (MIND), June 2012 12. X-Prize Foundation Visioneering 2012, Keynote talk June 2012 13. Families of SMA, June 2012 14. FutureMed 2012, Singularity University, February 2012 15. Northeastern University. Translational Imaging in drug discovery and development. 2011 16. 1st International Congress on Alzheimer’s Disease and Advanced Neurotechnologies, Monaco, 2010. 17. Novartis Pharmaceutical Corporation, 2009, Patient Centricity Forum 18. Merck Research Laboratories annual Scientific Symposium 2008, Plenary Talk 19. Merck research Laboratories, Boston symposium on Cerebral Blood Flow, 2007 20. MRL Technology symposium, Jersey Shore, New Jersey 2006 21. Epo conference, Lubeck, Germany, 2006 22. NIH, Conference on Hypoxia signaling, 2006 23. U MD, Sch. Of Medicine, 2006 24. U Michigan, Sch. Of Medicine, Ann Arbor, 2006 25. Merck & Co., Inc, Rahway, NJ, 2006 26. Hermelin Brain Tumor Center, Detroit MI, February, 2006 27. Indiana University, October 2005 28. Oxygen Club of Washington D.C., Annual Meeting, September 2005 29. University of Rochester, November 2004 30. Oxygen club of Washington, D.C., NIH Radiation Biology, March 2003. 31. International Conference on Traumatic brain injury, San Juan, PR, January, 2003. 32. NHLBI, Laboratory of Hematology, June, 2002 33. NINDS Laboratory of Molecular Pathology, Bethesda, MD, February 2001. 34. U.S. House of Representative, Washington D.C., July 200 35. NIA Laboratory of Neuroscience, Baltimore MD, September 2001 36. Center for Prostate Disease Research, Rockville, February 2001. 37. American Academy of Neurology, Toronto, Canada, May 1999. 38. International Brain Research Institute Meeting, Quebec City, Quebec, Canada, July

1999. 39. Society for Neuroscience Annual Meeting, Washington D.C., November 1998. 40. Institute of Medicine, National Academy of Science, Washington D.C., September

1998. 41. American Academy of Neurology, Minneapolis, MN, May 1998. 42. USUHS Research Day, Plenary Lecture, April 1998. 43. National Institutes of Health, Ataxia Telangectasia Children’s Project, March 1998. 44. Johns Hopkins University, School of Medicine, Department of Neurology, Baltimore,

MD, 1996. 45. National Institutes of Health, NINDS, Stroke Branch, Bethesda, MD, 1996. 46. Georgetown University Hospital, Department of Neonatology, Washington, DC, 1996. 47. George Mason University, Fairfax, Virginia, 1995.

48. National Naval Medical Center, Department of Neurology, Bethesda, Maryland, 1995. 49. AMEDD Annual Neurology Conference, USUHS, Bethesda, MD, 1994. 50. Society for Neuroscience, Grass Lecture, Southern Illinois University, Department of

Neuroscience, Carbondale, Illinois, 1994. 51. International Life Sciences Institute World Congress on Caffeine, Santorini, Greece,

1993. 52. American Society of Pharmacology and Experimental Therapeutics, San Francisco,

California, 1993. 53. American Heart Association Meeting on Hypertension, San Francisco, California,

1993. 54. Walter Reed Army Institute of Research, Washington, D.C., 1993. 55. University of Maryland, College Park, Program in Molecular and Cell Biology, 1990. 56. ICI Pharmaceuticals, Wilmington, DE, 1990. 57. Johns Hopkins University, School of Medicine, Department of Radiology, 1989. 58. Wilmer Eye Institute, Johns Hopkins School of Medicine, 1988.